Brandon W. Higgs

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 628 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Daniel K. Wells, Marit M. van Buuren, Kristen K. Dang et al. · Cell · 2020 · 536 citations · Full text

Life Sciences, Immunology, Oncology +16

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Suzanne I.S. Mosely, John E. Prime, Richard C.A. Sainson et al. · Cancer Immunology Research · 2016 · 423 citations

Medicine, Immunology, Oncology +16

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

Brandon W. Higgs, Zheng Liu, Barbara White et al. · Annals of the Rheumatic Diseases · 2011 · 408 citations

Life Sciences, Immunology, Molecular Medicine +17

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade

Qu Zhang, Jia Luo, Song Wu et al. · Cancer Discovery · 2020 · 336 citations · Full text

Medicine, Immunology, Oncology +17